Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -2.22% 44.00 43.70 44.30 44.40 43.80 44.00 1,157,157 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.7 200

Ekf Diagnostics Share Discussion Threads

Showing 4001 to 4025 of 4525 messages
Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
Morning wan - still waiting for the usual pal. Tic toc
Mg must agree with your assessment. Do you also believe second coming of the lord is also at hand? Lol
Due for tick up soon to mid 80,s since stable at current levels.
News from Medica 2021 (apologies wan if you've already posted this! I don't recall it....)


"EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
By LabMedica International staff writers
Posted on 15 Nov 2021

EKF Diagnostics (Cardiff, Wales, UK) showcased its recently launched STAT-Site WB β-ketone and glucose handheld analyzer at this year’s MEDICA, the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals....

....MEDICA 2021 became the venue for the first public viewing of the new STAT-Site WB β-ketone and glucose handheld analyzer in Europe since its global launch earlier this year. The STAT-Site WB analyzer from EKF is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples. The STAT-Site WB analyzer uses two different strips to provide results in just ten seconds for β-ketones and five seconds for glucose allowing for clear and comprehensive management of diabetes patients displaying early symptoms of ketosis to be quickly treated and then monitored on a regular basis.

EKF also demonstrated its globally successful PrimeStore MTM (Molecular Transport Medium) molecular transport media that gives the user a “snapshot” in time for that sample by preserving and stabilizing DNA and RNA. PrimeStore MTM was designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses, and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications.

In addition to PrimeStore MTM, EKF also demonstrated new product innovations relating to the future control of COVID-19, including the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory without the need for proprietary equipment."

Yes you have been staying that for a very long time. Shame you have tuned out any info received by Mr Market but rather insist on you being 100% certain what the future holds. As the wise man said - uncertainty is uncomfortable but certainty (in this universe) is absurd. Good luck old chap.
As I stated at the beginning of the above post, EKF are expanding way beyond COVID related testing, which the following exemplifies -

Welcome to the team, Michael T. Murphy!

With more than 25 years of experience in the Life Sciences industry, Michael’s new role is the Global Business Development Manager for Molecular Diagnostics and Custom Contract Manufacturing Services.

Great things keep coming our way.

Luke Daum
Chief Scientific Officer at EKF Diagnostics

Excited to have Michael onboard at EKF. He brings a wealth of knowledge from his experience at GEHC and beyond. Looking forward to working closely with an experienced Business Development expert to expand our diagnostics products and services at EKF!

Agreed! Extremely exciting times ahead

Michael has extensive experience and key relationships from operating at the top level, including GE Healthcare/Cytiva and Thermo Fisher. Worth checking out -

Beyond those excellent employees already onboard at EKF, EKF are attracting further high-calibre people, which also says a lot about EKF itself and indeed what the future holds!

EKF are expanding way beyond covid related testing etc, but nonetheless I believe the following is, at least, a very interesting development.

Yesterday the FDA issued new guidance on Emergency Use Authorization requests on certain types of SARS-CoV-2 tests. As such, the FDA's previous policies did not increase the availability of at-home tests, tests with home specimen collection, or other tests for use outside of a high-complexity CLIA-certified laboratory, including most POC tests, which the FDA is now looking to accommodate, but with a focus on increasing the availability and increased capacity -

FDA, HHS Update COVID-19 Test Emergency Use Authorization Policies
Nov 15, 2021

NEW YORK – The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

In the new document, FDA said it intends to focus its review of Emergency Use Authorization requests on certain types of SARS-CoV-2 tests, including at-home and point-of-care diagnostic tests for use with or without a prescription that can be manufactured in high volumes, i.e., with a manufacturing capacity of at least 500,000 tests per week within three months of receiving EUA.

The agency will also focus on high-volume, lab-based molecular tests — as well as home collection kits for use with these tests — that can expand testing capacity and accessibility, whether through pooling specimens to increase throughput, testing specimens collected at home and shipped to a lab, screening asymptomatic people, or detecting multiple respiratory viruses at once. These tests should also be from experienced developers who have indicated the ability to scale up manufacturing capacity, FDA noted.

Certain lab-based and POC high-volume antibody tests that can measure the amount of antibodies or amount of neutralizing antibodies are also part of the guidance, as well as tests that are supported by a US government stakeholder, such as the Biomedical Advanced Research and Development Authority or the National Institutes of Health's Rapid Acceleration of Diagnostics initiative.

Developers of other kinds of tests not mentioned in the guidance document can pursue market authorization through other pathways, including 510(k) clearance or de novo classification, the agency said.
Full story - hTTps://

Regarding home specimen collection, PrimeStore MTM effectively already has 510k approval via De Novo certification, and PBS/saline transport media are generally exempt from premarket notification requirements under 510(k) subject to complying with ISO 13485 and FDA Quality System Regulations.

So, EKF's sample collection products are not subject to any of the new restrictions, but developers of new tests would need to satisfy that over 500,000 specimen collection kits can be manufactured and supplied per week. And aside from EKF's industrial partner testing efforts, the acquisition of ADL Health CLIA certified laboratory that's processing thousands of samples on a daily basis, also looks timely given the high-throughput 'fast' testing capability and increasing capacity.

Notes from the FDA document -
"In order for diagnostic tests to significantly increase testing capacity, which has been identified as a US government testing priority, they should be high volume and high throughput and for use on broad patient populations (i.e., not only on symptomatic patients or patients suspected of COVID-19). FDA authorization of high and moderate complexity tests with manufacturing capacities lower than 500,000 tests per week will not sufficiently scale US testing capacity."

"Home specimen collection kits intended for use with high volume and high throughput laboratory-based tests will support and enable increased testing with such tests by increasing their accessibility."

If you scroll down to the bottom of the document to the flow chart, readers will see that for all types of tests, including those utilising home specimen collection kits, that unless high manufacturing capacity is 'in place', the FDA will decline those applications.

To my mind/interpretation, at the very least, this adds to the positive backdrop and underscores EKF as both a current and potential partner of choice on a number of fronts!

Please conduct you own research and make your own interpretations when making investment decisions, as mine could be either wrong or inaccurate.

Looks like a nice 750,000 share buy at 83p just reported.
Share price day's high on 9 Nov 2020 was 81. You're about there now as well. 0% return VS SPX returning about +30% over the period. Rumours are true - investing in a tracker works best for Joe Retail. Facts not fiction. Not sure how you calculate your performance but it doesn't really matter as long as this is a fan club innit. Lol
In my own humble opinion, EKF shares have performed quite well over the last few months when you consider other facts -

EKF has commenced investment in their 2021 – 2024 Growth Strategy, with significant investments in their UK and US operations:

> Work commenced on new fermentation facility with a total investment of $9.3m and the aim of delivering $20m in revenues by 2024.
> Continued expansion of contract manufacturing facilities in UK and USA.
> Investments into the global Point of Care business, including brand extensions and new product development.

Announced an earnings enhancing, cash generative acquisition, with the 9m Considerations Shares admitted to trading/absorbed 14 October 2021.
(not to mention director shares sales)

EKF's shares went Ex-dividend 4 November 2021 (Record date:5 November 2021 Payment date:1 December 2021).

So, I am far from disappointed with the share price performance. And with EKF entering a new era, enhanced by key strategic investments, and strong demand from industry partners, I am, to say the least, very optimistic about EKF's current and future prospects!

EKF wins twice at the 2021 Small Cap Awards
12th November 2021

EKF Diagnostics won two awards at the ninth annual Small Cap Awards that were announced yesterday evening in London.

Over 150 attendees, all supporters of the small cap community congregated at The Montcalm Hotel, Marble Arch, London black tie event. Companies and advisors were present at the ceremony hosted by Sarah Lowther, Editor-in-Chief at Master Investor.

The awards shine a light on the best companies and participants in the small and micro-cap community (sub £200m market capitalisation) across nine categories. They are a once-in-a-year opportunity to recognise outstanding achievement focused on smaller quoted companies.

EKF Diagnostics won Company of the year whilst Julian Baines picked up the Director of the Year. Both EKF and Julian are grateful for the nomination and the award, and delighted to receive recognition from the investment community.

The full list of winners were as follows:

You've been so in 2019 darling so not sure you've got a good enough track record. Btw the lord will also come back at some point in the indeterminate longer term. LOL
Looks like my timing was wrong for a breakout.

Silly me.

But it is no secret that we've been in a tight range since Sep now. I think we will get some news this month to take us out of this range upwards.

I am still confident we will see new highs before YE21.


If only Mr Market would understand the implication of such arguments... what's wrong with him ...
Following on from my post regarding US efforts and investment to increase availability and capacity for rapid molecular testing and rapid point-of-care molecular testing. The following may just be coincidental, but I have been monitoring the availability of Amazon's retail COVID-19 test collection kit in the US, which has been showing as out of stock for months, but is now in stock and available in the US at $36.99.

EKF's coverage in the above post shows they have increased their exposure to COVID-19 testing by now providing a sample-to-result service. And like Amazon, ADL Health offers an on receipt of a test at the lab, results are delivered within 24 hours. "This is accomplished by adapting the test to a fast, reliable high throughput format which provides results for thousands of samples on a daily basis. ADL is working around the clock to ensure healthcare providers, managed care facilities, employers, state and local governments and more, from across the U.S., secure the results they need for their workforces and communities."

However, whilst that COVID testing capability and capacity is likely to add further wind to EKF's sails (EKF already stated that they believe the acquisition represented a highly attractive and earnings accretive transaction), it is the expanding range of testing capabilities (beyond COVID-19) across a broader suite of healthcare applications that I am very interesting to see materialise.

I see this expanding range of testing capabilities immediately put in place by the acquisition, and indeed by further investment from EKF in ADL Health, as also being key in terms of satisfying EKF's industry partners testing requirements. And indeed to realise the potential to link to Trellus, Renalytix and Verici, who are likely to also need the testing capability and capacity to further support their commercial strategies as they unfold and expand.

Additional coverage of the already reported acquisition of Advanced Diagnostic Laboratory -

11th November 2021

EKF Diagnostics acquires ADL Health molecular diagnostic testing laboratory

ADL annoucenment

EKF Diagnostics, the global in vitro diagnostics company, announces that it has acquired Advanced Diagnostic Laboratory LLC (“ADL Health”), a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high-complexity molecular diagnostics testing. ADL Health’s CLIA-certified laboratory covers the fields of clinical, forensic and microbiological tests. The business has ISO 15189 Medical Laboratory accreditation giving it recognition in 44 countries and reflecting ADL Health’s commitment to high standards.

Using its expertise in PCR testing, ADL Health also provides COVID-19 testing needs for dozens of Fortune 500 companies and government agencies. For example, it is a pre-travel COVID-19 testing partner for Air Canada and United Airlines. In addition, ADL Health is expanding its range of testing capabilities across a broader suite of healthcare applications. Under EKF’s ownership, further investment is anticipated to support the deployment of additional equipment and personnel in order to service customer demand.

ADL Health delivers a range of rapid and accurate COVID-19 testing services. Considered the gold standard, due to its precision, ADL’s COVID-19 rRT-PCR test has the capability to detect infection in its earliest stages and ensure a quick turnaround time. On receipt of a test at the lab, results are delivered within 24 hours. This is accomplished by adapting the test to a fast, reliable high throughput format which provides results for thousands of samples on a daily basis. ADL is working around the clock to ensure healthcare providers, managed care facilities, employers, state and local governments and more, from across the U.S., secure the results they need for their workforces and communities.

In addition to corporate and group high-volume COVID testing, ADL Health provides a range of testing options including HomeCollect™ which is a kit-based home testing service delivering results back within 24 hours. ADL also has a rapid response team ready to be deployed to a business or organization for on-site testing within hours to help prevent loss of business due to a COVID shutdown. The laboratory also offers a drive-thru COVID testing service, as well as a COVID pass digital health app for travelers to present standardized, verifiable proof of a negative COVID test.

While the growth of ADL Health has been accelerated by its COVID testing capabilities, its wider testing offering, including current and planned capabilities, both complement and broaden EKF’s existing diagnostics portfolio, which include test kit manufacturing and point-of-care diagnostic instrumentation.

Mike Salter, Chief Executive Officer of EKF, commented: “The acquisition of ADL Health affirms EKF’s position as a leading provider of diagnostic products and services, including a testing offering that our industry partners have been looking for us to provide. The ability to offer testing for a wide range of diseases, combined with our existing point-of-care device, reagent, sample collection, kitting and manufacturing services, positions us as a single provider able to encompass all products and services from ‘sample-to-result’.

Stanley Crawford III, COO and Founder of Advanced Diagnostic Laboratory added: “We are excited to become a member of the EKF Diagnostics family. The combination of a premier CLIA lab with a powerhouse such as EKF not only creates a whole new capability for the Group but also provides the combined Group with compelling opportunities to drive growth by meeting more of our clients’ needs.”

Very informative wan ta - share price not obliging but gms of the world are after a good story. Lol
The US government has already made significant investments to increase availability and capacity of rapid lateral flow test. The follow on from that strategy, if you receive positive result, is that you will need commensurate capacity for PCR testing, which of course requires an appropriate sample, and the sooner the result is available the better.

The following outlines the next stage of the US testing strategy for rapid molecular testing and rapid point-of-care molecular testing, which also includes sustaining robust long-term manufacturing in the US -

November 10, 2021

Biden Administration to Invest $650 Million in Rapid Diagnostic Testing in Latest Action to Increase Access to Tests

Funding Will Expand and Sustain Testing Capacity for Hospitals, Urgent Care, Pharmacies and Other Community Health Care Settings to Help Health Care Providers Quickly Confirm At-Home Test Results As More Americans Turn to At-Home Rapid Testing

As part of the Biden-Harris Administration’s ongoing commitment to increasing access to COVID-19 testing for Americans and to further strengthen domestic manufacturing of needed tests, the U.S. Department of Health and Human Services (HHS) will invest $650 million from the American Rescue Plan to strengthen manufacturing capacity for quick, high-quality diagnostic testing through rapid point-of-care molecular tests and increase Americans’ access to them.

As at-home testing increases, the need for follow-up testing in health care settings will likely grow. For example, if someone buys an over-the-counter rapid antigen test at their local pharmacy to take at home and tests positive, they may seek out a health care provider who would conduct another test to confirm that result. This new investment will help ensure tests like these are readily available across the country and can provide results quickly.

“Access to fast, accurate, and reliable tests help keep Americans safe and healthy,” said HHS Secretary Xavier Becerra. “Thanks to the American Rescue Plan, we are increasing our testing supply, investing in American manufacturers, and continuing to support these critical tools for getting the pandemic under control.”

Hospitals, urgent care centers, pharmacies and other community health care settings use rapid molecular tests to diagnose COVID-19, screen patients before surgery without unnecessary delays, identify people who may benefit from COVID-19 therapies, and confirm at-home test results.

To support access to this type of diagnostic testing, HHS will use these funds to ramp up U.S. domestic manufacturing capacity. By strengthening our ability to produce these tests in the United States, we will minimize our reliance on imports from overseas, and sustain robust long-term manufacturing throughout 2022. The funding will also support purchasing raw materials and finished tests to increase our domestic supply of diagnostic tests.

This initiative builds on recent efforts by the Biden-Harris Administration to strengthen testing and make tests more available nationwide. President Biden recently announced $3 billion in new investments in rapid testing. These resources will grow the supply of rapid tests, including quadrupling the supply of at-home tests by the end of the year. HHS also recently announced a series of actions to help reduce costs, make tests more available, and support bringing more over-the-counter tests to market in the U.S.

PrimeStore MTM has been validated on a number of rapid POC molecular platforms (improving the performance of some).

Other molecular transport media can also be used, such as PBS (and ATM).

Fair to say our dear gm did not have the slightest clue (for a change) on what he was talking about the other day? Lol.
Tool of the week award!
melody9999 - no, it was released a month ago which is when rivaldo picked it up. The Citywire article was based on the same so they have had it on the desk for a month waiting a spare slot.


Citywire probably picked this up from the latest Free Spirit monthly report which was released less than a week ago.
Sharw, good to see I'm a month ahead of Citywire then :o))
I note the Deputy Chairman's share sale yesterday.

Staying with diagnostic testing:

Given anything that UK government announces is usually altered, fail to materialise as implied, or runs at a snail's pace, I would not hang my hat on the following, but it at least provides for a positive backdrop in terms of UK diagnostics coming up the agenda and especially in terms of pandemic preparedness and resilience, with some in the sector welcoming the details. Budget excerpt/details -

Describing it as the “highest real-terms core capital budget for health since 2010”, Mr Sunak promised a “step change” in quality and efficiency of care, with £2.3 billion for increased diagnostic capacity and £2.1 billion to support the innovative use of digital technology.

The Chancellor promised £2.3 billion for at least 100 “community diagnostic centres” in England. The one-stop shops will see cancer tests offered in shopping centres and football stadiums in a bid to detect the disease sooner.

In further related news -

UK announces £248m funding to digitise diagnostics care
08 Nov 2021 (Last Updated November 8th, 2021 09:29)
The digitisation of diagnostics services across NHS hospitals will accelerate treatment for patients

The UK Government has announced funding of £248m ($334.6m) for the National Health Service (NHS) with an aim to digitise diagnostics care and address the problem of patient waiting lists.

The funding, which will be received over the next year, will be invested by the NHS in technology to provide more diagnostic services and quicker scans, leading to accelerated treatment for patients.

The digitisation of diagnostics services across NHS hospitals will help reduce the administrative burden on staff, who in turn can dedicate more time to scans, tests and checks.

This approach will also help reduce the turnaround time from a patient taking a test to the commencement of appropriate treatment.

Across the NHS, digitisation will also lead to the sharing of tests, images and results with hospitals, labs and general practitioners (GPs) using computer systems.

UK Health and Social Care Secretary Sajid Javid said: “The multi-million-pound investment will play a big role in levelling up diagnostics services across the country so patients can get faster results and healthcare professionals can get their job done more easily, reducing unnecessary administrative burden, and making every taxpayer’s pound count.

“Getting a faster diagnosis for a health condition is the first step to getting more people the treatment they need and earlier on, and our funding will help ensure our NHS has access to the latest digital technology to drive up efficiency.”

Annually, more than 1.5 billion diagnostic tests are conducted in England to rule out or confirm medical conditions.

Recently, the UK Government announced £2.3bn ($3.1bn) of funding to transform diagnostic services.

This funding will help open at least 100 new community diagnostic centres across England.

Full story - hTTps://

Maybe the prospects for UK diagnostic will indeed see dynamic change!

Rivaldo - good though the article is, it is just a repeat, a month after the original, which you posted here (post 2333).
Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221206 01:43:20